-
Researchers to reveal trial results for dual agonism in type 1 diabetes
Experts, including Klara Klein, MD, PhD, will discuss the possible benefits of a glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor agonist (GLP-1/GIP RA) for people living with type 1 diabetes.
-
Symposium to analyze amylin as novel therapy for diabetes and weight loss
W. Timothy Garvey, MD, and other researchers will share new insights from trials, such as REDEFINE, exploring long-acting amylin analogs as mono-agonists and in combination with agonists for other hormone receptors.
Scientific Sessions Newsmakers
-
Experts to reveal results of retatrutide trials TRANSCEND-T2D-1 and TRIUMPH-1
Jonathan Campbell, PhD, and other panelists will share new data and address how this triple-hormone receptor agonist may unlock the next frontier of treatment for obesity and type 2 diabetes.
-
Primary results for SOLSTICE and VISTA to be shared for the first time
Vanita R. Aroda, MD, and Melanie Davies, CBE, MBChB, MD, FRCP, FRCGP, FMedSci, will review the latest data for a novel oral glucagon-like peptide-1 receptor agonist in people living with with type 2 diabetes or overweight or obesity.
-
Presenters to provide first look at data from REIMAGINE trials of cagrilintide/semaglutide for type 2 diabetes management
John B. Buse, MD, PhD, and other researchers will share study results and a broad understanding of amylin, from the hormone’s biology to potential translation to clinical care via phase 3 trials.
-
Trending topics in diabetes and obesity research and care highlight the 2026 Scientific Sessions program
Experts from across the globe will offer new perspectives on obesity, artificial intelligence, liver disease, behavioral health, women’s health, nutrition, new technology, and other trending topics in diabetes this June in New Orleans.
-
New clinical trial results to debut daily in New Orleans
Investigators will present high-impact results for type 1 diabetes, type 2 diabetes, and obesity in several clinical trial sessions. Glucagon-like peptide-1 (GLP-1)-based therapies—including dual and triple agonists, oral agents, and longer acting formulations—will be a recurring topic.
-
Maximize your Scientific Sessions experience through engagement
Rita R. Kalyani, MD, MHS, the ADA’s Chief Scientific and Medical Officer, encourages participants in New Orleans to come ready to delve deeper into their core areas of expertise and to seize opportunities to explore new ideas.